A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

• Sponsor: Janssen Research & Development, LLC (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT04606381
• Collaborator: (none)
• Enrollment: 196
• Locations: 14
• Arms: 3
• Anticipated Duration (Months): 46.7
• Patients Per Site: 14
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Malignancies	Drug: Ami-LC-MD; Drug: Ami-LC; Drug: Ami-HC; Drug: Ami-HC-CF; Drug: Lazertinib	Phase 1

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 196 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies
• Actual Study Start Date: Nov 10, 2020
• Anticipated Primary Completion Date: Apr 3, 2023
• Anticipated Study Completion Date: Oct 2, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part 1: Ami-LC-MD and Ami-LC Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.	Drug: Ami-LC-MD; Participants will receive amivantamab admixed with rHuPH20 SC infusion.; Drug: Ami-LC; Participants will receive amivantamab SC infusion.
Experimental: Part 2: Ami-HC and Ami-HC-CF Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).	Drug: Ami-HC; Participants will receive amivantamab newly developed high concentration SC infusion.; Drug: Ami-HC-CF; Participants will receive amivantamab co-formulated with rHuPH20.
Experimental: Part 3: Ami-HC-CF + Lazertinib and Ami-HC+ Lazertinib Participants will receive SC infusion of either Ami-HC-CF or Ami-HC in combination with lazertinib tablet.	Drug: Ami-HC; Participants will receive amivantamab newly developed high concentration SC infusion.; Drug: Ami-HC-CF; Participants will receive amivantamab co-formulated with rHuPH20.; Drug: Lazertinib; Participants will receive lazertinib orally as a film-coated tablet.; Other Names: JNJ-73841937 YH25448

Outcome Measures

Primary Outcome Measures

1. Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) [Up to Day 29]

   Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration.

2. Amivantamab Steady-state Area Under the Curve (AUCss) [Cycle 4 (28 days)]

   AUCss is defined as the area under the curve for amivantamab at steady state.

3. Number of Participants with Adverse Event (AE) [Up to 4 years 1 month]

   An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

4. Number of Participants with Dose Limiting Toxicity (DLT) [Up to Day 28]

   Number of participants with DLT will be assessed.

5. Number of Participants with Clinical Laboratory Abnormalities [Up to 4 years 1 month]

   Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed.

Secondary Outcome Measures

1. Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies [Up to 4 years 1 month]

   Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed.

2. Part 3: Plasma Concentration of Lazertinib [Up to 4 years 1 month]

   Plasma samples will be analyzed to determine concentrations of lazertinib using a validated method.

3. Epidermal Growth Factor Receptor (EGFR) Concentrations [Up to 4 years 1 month]

   EGRF concentrations markers will be assessed.

4. Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers [Up to 4 years 1 month]

   cMET markers will be analyzed.

5. Overall Response Rate (ORR) [Up to 4 years 1 month]

   ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1.

6. Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State [Up to 4 years 1 month]

   Maximum amivantamab dosing interval Between time zero to steady state will be assessed.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion criteria:

• Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records; Part 3: Participants with histologically or cytologically confirmed NSCLC with previously identified EGFR mutation (identified locally in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory [or equivalent]) that is metastatic or unresectable and have progressed on or after at least one line of standard of care systemic treatment for metastatic disease. Required prior therapy includes an approved anti-EGFR tyrosine kinase inhibitor (TKI), or in the case of EGFR exon 20 insertion mutation disease, platinum-based chemotherapy. A participant who has refused all other currently available therapeutic options is allowed to enroll and must be documented in the study records

• Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug

• A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug

• A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])

Exclusion criteria:

• Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded

• Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels

• Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible

• Participant has an active malignancy other than the disease under study requiring treatment

• Participant has leptomeningeal disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cedars Sinai Medical Center	West Hollywood	California	United States	90048
2	Community Health Network	Indianapolis	Indiana	United States	46256
3	Langone Health at NYC University, NYU School of Medicine	New York	New York	United States	10016
4	Providence Portland Medical Center	Portland	Oregon	United States	97213
5	Sarah Cannon Research Institute	Nashville	Tennessee	United States	37203
6	The Ottawa Hospital - General Campus	Ottawa	Ontario	Canada	K1H 8L6
7	University Health Network	Toronto	Ontario	Canada	M5G 2M9
8	Chungbuk National University Hospital	Cheongju-si		Korea, Republic of	28644
9	Seoul National University Bundang Hospital	Seongnam-si		Korea, Republic of	13620
10	Seoul National University Hospital	Seoul		Korea, Republic of	03080
11	Severance Hospital, Yonsei University Health System	Seoul		Korea, Republic of	03722
12	Samsung Medical Center	Seoul		Korea, Republic of	06351
13	The Christie Nhs Foundation Trust	Manchester		United Kingdom	M20 4BX
14	Royal Marsden Hospital	Sutton		United Kingdom	SM2 5PT

Sponsors and Collaborators

• Janssen Research & Development, LLC

Investigators

• Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Janssen Research & Development, LLC
• ClinicalTrials.gov Identifier: NCT04606381
• Other Study ID Numbers: CR108891; 2020-003225-36; 61186372NSC1003
• First Posted: Oct 28, 2020
• Last Update Posted: Jul 21, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Janssen Research & Development, LLC: Amivantamab; JNJ-61186372
• Additional relevant MeSH terms: Neoplasms; Lazertinib

Study Results

No Results Posted as of Jul 21, 2022